View Past PerformancePrecigen 대차대조표 건전성재무 건전성 기준 점검 4/6Precigen 의 총 주주 지분은 $20.9M 이고 총 부채는 $93.2M, 이는 부채 대 자기자본 비율을 445.6% 로 가져옵니다. 총자산과 총부채는 각각 $155.5M 및 $134.6M 입니다.핵심 정보445.57%부채/자본 비율US$93.17m부채이자보상배율n/a현금US$97.86m자본US$20.91m총부채US$134.59m총자산US$155.51m최근 재무 건전성 업데이트Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price RuleNov 09We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn RateFeb 28Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?Jul 18모든 업데이트 보기Recent updatesExecutive Chairman recently sold US$7.7m worth of stock Apr 07Consensus revenue estimates increase by 17% Apr 01New minor risk - Share price stability Mar 26Full year 2025 earnings: EPS and revenues miss analyst expectations Mar 26Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has) Mar 26Precigen, Inc. to Report Fiscal Year 2025 Results on Mar 25, 2026Mar 12Precigen, Inc. Announces the Publication for The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory PapillomatosisJan 20Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-And-Only Fda-Approved Therapy for RRPJan 13Executive Chairman notifies of intention to sell stock Dec 24Independent Director recently sold US$856k worth of stock Dec 19Independent Director recently sold US$856k worth of stock Dec 18Independent Director notifies of intention to sell stock Dec 15Executive Chairman notifies of intention to sell stock Nov 20Consensus EPS estimates fall by 124%, revenue upgraded Nov 20Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 14New minor risk - Shareholder dilution Nov 14Precigen, Inc. to Report Q3, 2025 Results on Nov 13, 2025Nov 07Precigen, Inc. Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses After Treatment with PapzimeosOct 13Executive Chairman recently sold US$6.2m worth of stock Oct 02New minor risk - Insider selling Oct 01Independent Director notifies of intention to sell stock Sep 30Executive Chairman notifies of intention to sell stock Sep 19Precigen, Inc. announced that it expects to receive $125 million in fundingSep 03Consensus EPS estimates fall by 13%, revenue upgraded Aug 19Price target increased by 18% to US$7.25 Aug 15Precigen, Inc. Announces Full FDA Approval of PAPZIMEOS (Zopapogene Imadenovec-Drba)Aug 15Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 13Consensus revenue estimates increase by 24%, EPS downgraded May 21President exercised options and sold US$756k worth of stock May 18Forecast breakeven date pushed back to 2027 May 16First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind May 15Precigen, Inc., Annual General Meeting, Jun 26, 2025May 08Consensus revenue estimates fall by 25% Mar 26Full year 2024 earnings: EPS and revenues miss analyst expectations Mar 20Precigen, Inc. to Report Fiscal Year 2024 Results on Mar 19, 2025Mar 13Consensus revenue estimates increase by 42% Mar 03Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement Feb 28Precigen, Inc. Announces FDA Grants Priority Review to its BLA for PRGN-2012 for Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025Feb 26Precigen: Successful Proof Of Platform, But Cash Worries Remain Feb 10Precigen, Inc. announced that it has received $79 million in fundingJan 01New minor risk - Share price stability Dec 30Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory PapillomatosisDec 30Precigen, Inc. announced that it expects to receive $79 million in fundingDec 29Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 15Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price RuleNov 09Consensus revenue estimates fall by 12% Aug 21Price target decreased by 41% to US$6.00 Aug 16Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 15Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024Aug 09+ 1 more updateNew minor risk - Shareholder dilution Aug 08Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.Aug 07+ 1 more updateNew minor risk - Share price stability Aug 04Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial OfficerJul 23Price target increased by 11% to US$10.12 Jun 16Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete ResponseJun 05Price target increased by 11% to US$10.12 Jun 04Precigen, Inc., Annual General Meeting, Jul 05, 2024May 31Consensus revenue estimates fall by 10% May 21Price target increased by 40% to US$9.12 May 17First quarter 2024 earnings: EPS and revenues miss analyst expectations May 15Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024May 10Price target decreased by 27% to US$6.50 May 09Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse ImmunotherapyApr 25President exercised options and sold US$575k worth of stock Apr 11Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 20Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024Mar 06We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn RateFeb 28Precigen: RRP Targeting With AdenoVerse Technology Platform Jan 20Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionJan 17Independent Director recently sold US$136k worth of stock Dec 31Forecast to breakeven in 2026 Dec 31Consensus revenue estimates fall by 11% Nov 16Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?Nov 04Independent Director recently bought US$688k worth of stock Aug 17Consensus revenue estimates decrease by 12%, EPS upgraded Aug 16Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 10Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated ApprovalAug 10President exercised options and sold US$58k worth of stock Aug 06Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023Aug 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?Jul 18Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisJun 22Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer PatientsJun 06Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated CancersJun 04Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical CancerJun 01Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's DowngradeMay 15First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 11Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023May 04Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S RatioApr 18Full year 2022 earnings: EPS in line with expectations, revenues disappoint Mar 07Precigen, Inc. Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory PapillomatosisJan 25Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare ConferenceJan 12Consensus revenue estimates increase by 34% Nov 16재무 상태 분석단기부채: PGEN 의 단기 자산 ( $115.2M )이 단기 부채( $37.3M ).장기 부채: PGEN의 단기 자산($115.2M)이 장기 부채($97.3M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: PGEN 총 부채보다 더 많은 현금을 보유하고 있습니다.부채 감소: PGEN의 부채 대비 자본 비율은 지난 5년 동안 255.9%에서 445.6%로 증가했습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: PGEN 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: PGEN 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/30 12:22종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Precigen, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ying HuangBarclaysDerik de BruinBofA Global ResearchJustin WalshB. Riley Securities, Inc.7명의 분석가 더 보기
Precigen, Inc. Announces the Publication for The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory PapillomatosisJan 20
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-And-Only Fda-Approved Therapy for RRPJan 13
Precigen, Inc. Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses After Treatment with PapzimeosOct 13
Precigen, Inc. Announces FDA Grants Priority Review to its BLA for PRGN-2012 for Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025Feb 26
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory PapillomatosisDec 30
Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.Aug 07+ 1 more update
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete ResponseJun 05
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse ImmunotherapyApr 25
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionJan 17
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated ApprovalAug 10
Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisJun 22
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer PatientsJun 06
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated CancersJun 04
Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical CancerJun 01
Precigen, Inc. Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory PapillomatosisJan 25
Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare ConferenceJan 12
